Skip to main content

Table 3 Use of anticoagulants

From: Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit

 

Patients (n = 1,935)

Patient-days (n = 12,756)

Prophylactic anticoagulants

  

 Subcutaneous LMWH

535 (27.6)

2,687 (21.1)

 Subcutaneous UFHa

1,044 (54.0)

5,504 (43.1)

Therapeutic anticoagulants

  

 Any therapeutic anticoagulant

390 (20.2)

1,693 (13.3)

 Intravenous UFH

284 (14.7)

1,210 (9.5)

 LMWH

35 (1.8)

119 (0.9)

 Coumadin

94 (4.9)

324 (2.5)

 Danaparoid

5 (0.3)

7 (0.05)

 Otherb

52 (2.7)

168 (1.3)

Any of the above

1,619 (83.7)

9,589 (75.2)

  1. Anticoagulation management for the 1,935 patients included in this audit, and ICU patient-days. Some patients received more than one type of anticoagulation during their ICU stay. LMWH, low molecular weight heparin; UFH, unfractionated heparin. aRefers to doses of UFH that were not ordered to target an activated partial thromboplastin time. bThrombolytic agents (streptokinase, recombinant tissue plasminogen activator), argatroban, fondaparinux, eptifibatide, dabigatran, rivaroxaban.
Back to article page

Critical Care

ISSN: 1364-8535